Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829466 | 0.98 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL18297996 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL829571 | 0.85 | NCEH1 (0.51) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL25249468 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL25243647 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL21089037 | 0.84 | TP53 (0.51) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL25286920 | 0.84 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL20887181 | 0.81 | NPSR1 (0.70) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL829640 | 0.81 | GAA (0.64) | SMN1; SMN2ALDH1A1GAANPC1HPGD | |
| SCHEMBL20626906 | 0.81 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1GAANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626891-A | Synthesis method of nilapanib key intermediate | 四川轻化工大学 | 2023-01-20 | — | — | CN | claimed |
| CN-110300587-B | Deuterated (S) -2- (4- (piperidin-3-yl) phenyl) -2H-indazole-7-carboxamide | 康姆芘法思催化剂股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4204415-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-115626891-A | Synthesis method of nilapanib key intermediate | 四川轻化工大学 | 2023-01-20 | — | — | CN | disclosed |
| CN-110156751-B | Novel method for preparing nilapanib and intermediate thereof | 江苏食品药品职业技术学院 | 2022-01-18 | — | — | CN | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | SMN1; SMN2 4842/4885ALDH1A1 936/4885GAA 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.